| abstract |
Provided herein are predictive diagnostics, pharmacodynamics and methods of treatment, particularly for the treatment of breast cancer. In embodiments, the methods and compositions comprise an estradiol (E2) derived score or estrogen determined from a sample of an individual (e.g., a tissue sample, e.g., a tumor tissue sample, e.g., FFPE, FF, stored, fresh or frozen tumor tissue sample). The receptor (ER) pathway activity score determines whether an individual with breast cancer is likely to respond to treatment, including endocrine therapy; Selecting treatments for individuals with breast cancer; Treating individuals with breast cancer; It is based at least in part on the findings that it can be used in related kits as well as methods of monitoring the therapeutic efficacy of endocrine therapy. |